硫辛酸使用者与非使用者的NELL1膜性肾病特征与结局
该多机构回顾性研究分析了70例NELL1膜性肾病患者,发现36%与硫辛酸相关,27%与重度非甾体抗炎药使用相关。中位随访11个月,72%达到完全或部分缓解;硫辛酸相关者且随访≥6个月缓解率达91%。多因素分析显示原发性NELL1膜性肾病和肾小管萎缩/间质纤维化程度更高者缓解可能性更低,而完全缓解与硫辛酸使用相关。
要点
- NELL1膜性肾病中硫辛酸相关占36%,停药可能是首选治疗。
- 硫辛酸相关且随访≥6个月者缓解率高达91%。
- 原发性NELL1膜性肾病和间质纤维化程度高者缓解率更低。
核心结论
- 研究强化了硫辛酸与NELL1膜性肾病的关联,提示停用硫辛酸而不使用免疫抑制可作为一线治疗考虑。
研究设计与样本
- 回顾性多机构队列研究,纳入3个机构的70例NELL1膜性肾病患者,中位年龄66岁,53%为男性,中位蛋白尿5.9 g/d。
主要发现
- NELL1膜性肾病与硫辛酸(36%)、重度非甾体抗炎药使用(27%)、自身免疫病(23%)、恶性肿瘤(近期10%,任何23%)、汞暴露(1%)相关,11%无已知继发关联。
- 中位随访11个月,72%达到完全或部分缓解;硫辛酸相关且随访≥6个月者缓解率为91%。
- 多因素分析中,原发性NELL1膜性肾病(调整OR 19.7,P=0.01)和肾小管萎缩/间质纤维化程度增加(调整OR 1.1,P=0.01)与任何缓解可能性更低相关。
- 完全缓解与硫辛酸使用(调整OR 10.9,P=0.04,95%CI 1.2-100)和较低间质纤维化程度(调整OR 0.79,P=0.16,95%CI 0.66-0.96)相关。
临床怎么用
- 对NELL1膜性肾病患者应详细询问硫辛酸暴露史,若相关可考虑停用硫辛酸而不立即使用免疫抑制。
- 肾活检提示间质纤维化程度较高者缓解可能性较低,需密切随访并个体化治疗。
局限性
- 回顾性研究设计,样本量有限,随访时间较短,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neural epidermal growth factor like 1 membranous nephropathy (NELL1 MN) is associated with various secondary etiologies. However, previous studies on the frequency of these associations and their impact on outcomes are limited. We report a large multiinstitutional series of patients with NELL1 MN with a focus on secondary associations, pathology findings, and their impact on outcome. METHODS: We retrospectively reviewed clinicopathologic features of NELL1 MN from 3 institutions and analyzed clinical and histologic associations with outcome. RESULTS: Of 70 patients, 53% were male with a median age of 66 years; median proteinuria was 5.9 g/d. NELL1 MN was associated with lipoic acid (36%), heavy nonsteroidal antiinflammatory drug (NSAID) use (27%), autoimmune disease (23%), malignancy (10% recent, 23% any), mercury exposure (1%), and 11% had no known secondary association. At median follow-up of 11 months, 72% achieved complete or partial remission. Remission rate was 91% in patients with lipoic acid-associated NELL1 MN and ≥6 months of follow-up. On multivariable analyses, patients with primary NELL1 MN (adjusted odds ratio [OR]: 19.7, P = 0.01) and increasing degree of tubular atrophy and interstitial fibrosis (IFTA) (adjusted OR 1.1, P = 0.01) were less likely to achieve any remission, whereas complete remission (CR) was associated with lipoic acid use (adjusted OR: 10.9, P = 0.04, 95% confidence interval [CI]: 1.2-100) and lesser degrees of IFTA (adjusted OR: 0.79, P = 0.16, 95% CI: 0.66-0.96). CONCLUSION: Our findings strengthen the association between lipoic acid and NELL1 MN. Furthermore, our findings suggest that discontinuation of lipoic acid without immunosuppression should be considered as the first-line treatment.
引用
- Avasare RS, Clark S, Spain RI, et al. Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers. Kidney Int Rep. 2024. PMID: 38707817. doi:10.1016/j.ekir.2024.02.1401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。